Global firms turn to M&A in EVs and biotech to deepen China investment: KPMG

A KPMG survey shows three in four multinational corporations operating in China have maintained or increased investments this year, focusing on mergers and acquisitions in electric vehicles and biotechnology. Despite geopolitical tensions, only 1% are preparing to exit the market.

A KPMG survey published on Monday shows that three in four multinational corporations (MNCs) operating in mainland China have maintained or increased their investments in 2025, despite Washington stepping up efforts to decouple from Beijing and its allies following suit. The survey, polling 137 senior executives from global companies in the world's second-largest economy between June and September, revealed that only 1 per cent reported preparing to exit the market. About 20 per cent said they may reduce investment, while the rest had yet to decide.

Companies planning to expand said they would pursue greenfield investment, mergers and acquisitions or joint ventures to deepen their China presence. "We have seen a significant increase in mergers and acquisitions activities among MNCs in China over the past six months," said Mark Harrison, partner and co-head of multinational clients at KPMG in China.

"In consumer-facing sectors, amid fierce local competition and challenging market dynamics, MNCs are pursuing vertical integration by acquiring distributors, agents and original equipment manufacturers to better understand and serve Chinese consumers," Harrison added.

The survey found optimism in life sciences, healthcare and manufacturing, with half forecasting revenue growth. Key sectors include electric vehicles, biotechnology and semiconductors, even amid regulatory challenges like the US Biosecure Act.

Artigos relacionados

Executives preparing vibrant booths for the 8th CIIE, featuring products from Johnson Health Tech, Theland, and Roche amid bustling expo hall.
Imagem gerada por IA

Firms gear up for eighth CIIE

Reportado por IA Imagem gerada por IA

As the eighth China International Import Expo (CIIE) approaches, companies are ramping up preparations, drawing on past successes. Firms like Johnson Health Tech, New Zealand's Theland, and Roche have achieved market breakthroughs and innovative partnerships through the event. The CIIE has become a vital platform for global businesses entering China.

Global institutional investors have built sizeable positions in China's largest biotech firms, including Innovent, 3SBio, WuXi Biologics, Jiangsu Hengrui, Akeso and BeOne. These companies, all constituents of the Hang Seng Biotech Index, are gaining importance on the global stage. Foreign investors, from sovereign wealth funds to industry players, are securing strategic stakes in their future success.

Reportado por IA

In 2025, Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms, totaling US$135.7 billion, up from 94 deals worth US$51.9 billion in 2024. Data released last week by China's National Medical Products Administration (NMPA) shows the number and value of these deals hit record highs, driven by dozens of multibillion-dollar agreements involving Hong Kong and mainland China-listed firms and international giants.

Apesar de uma correção no preço do bitcoin superior a 30%, o boom de fusões cripto de US$ 8,6 bilhões em 2025 —impulsionado por aquisições de licenças em meio à desregulamentação da era Trump— continuou acelerado, com analistas prevendo persistência até 2026. Isso complementou US$ 14,6 bilhões em IPOs, sinalizando maturação da indústria.

Reportado por IA

China is leveraging high-tech manufacturing, including 3D printers, to gain a competitive edge in global markets. In 2025, exports of high-tech products rose 13.2 percent, contributing to overall export growth. Shenzhen firms like Anycubic and Elegoo are expanding overseas through innovation and cost advantages, reaching over 150 countries and regions.

Cathy Zhang, head of Asia-Pacific equity capital markets at Morgan Stanley, predicts that 2026 could exceed last year's record IPO figures in Hong Kong, driven by January's momentum, with more than 450 companies already in the pipeline.

Reportado por IA

Tariffs may ebb and supply chains may detour, but US shoppers and giants like Walmart and Amazon still rely heavily on Chinese goods. At the National Retail Federation (NRF) showcase, attendees expressed more optimism for the year ahead.

segunda-feira, 02 de fevereiro de 2026, 20:56h

Can Hyundai Motor stage a comeback in China?

domingo, 25 de janeiro de 2026, 10:33h

Chinese tech listings shine in Hong Kong amid Beijing's self-reliance push

quarta-feira, 21 de janeiro de 2026, 08:51h

China's AI firms surpass 6000 in 2025

quarta-feira, 14 de janeiro de 2026, 16:15h

China's EV makers face slowdown in export growth after 2025 doubling

domingo, 11 de janeiro de 2026, 15:42h

Chinese entrepreneurs seek overseas residency to match business expansion

terça-feira, 30 de dezembro de 2025, 14:47h

México 2026: a oportunidade pendente em investimentos e nearshoring

sábado, 27 de dezembro de 2025, 04:42h

Greater Bay Area assets poised to lead surge in China’s C-REIT market

terça-feira, 23 de dezembro de 2025, 22:45h

C-beauty brands face slow retail expansion outside China

sábado, 20 de dezembro de 2025, 13:28h

Japan's M&A deals reach record $350 billion

terça-feira, 02 de dezembro de 2025, 21:09h

CIIE drives global firms' expansion in China

 

 

 

Este site usa cookies

Usamos cookies para análise para melhorar nosso site. Leia nossa política de privacidade para mais informações.
Recusar